BGB-11417

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
260 patients (estimated)
Sponsors
BeiGene
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1672
NCT Identifier
NCT04771130

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.